Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Grace Ordonez BA

Grace Ordonez BA

Clinical Research Project Manager, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women´s Hospital, Boston, Massachusetts

Grace Ordonez is the clinical research project manager of the Diabetes and Metabolic Disease Research Program at Brigham and Women’s Hospital. She partners with investigators, fellows, and coordinators to lead several clinical trials targeting diabetic cardiomyopathy, systemic inflammation, and treating type 2 diabetes with endoscopic treatment.

Grace holds a BA in Cellular, Molecular, and Genetics Biology from Boston University, and began her multidisciplinary clinical research career at Boston Children’s Hospital. At BCH, Grace coordinated spinal muscular atrophy studies for the Neuromuscular Research Program and was involved in the recruitment and conduct of two studies that led to the FDA approval of two SMA treatments. Grace then furthered her clinical research career in the Center for Clinical Investigations at Brigham and Women’s Hospital focusing on type 2 diabetes, respiratory (CLAD), newborn medicine (NBO system), and COVID-19 before taking on her new role as the project manager of the Diabetes and Metabolic Research Program. Her clinical research interests include type 2 diabetes, spinal muscular atrophy, and pulmonary critical care.

Recent Contributions to PracticeUpdate:

  1. Tirzepatide vs Semaglutide in Patients With Type 2 Diabetes